GSA Capital Partners LLP Has $865,000 Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Key Points

• GSA Capital Partners LLP increased its stake in IQVIA Holdings Inc. by 263% during the first quarter, with holdings valued at $865,000 as per its recent SEC filing.
• Insider Eric Sherbet sold 5,800 shares for over $1.1 million, reflecting a significant decrease in ownership, while a total of 1.60% of the stock is owned by corporate insiders.
• IQVIA recently reported earnings of $2.81 EPS, surpassing analyst expectations, with a revenue of $4.02 billion for the quarter, a year-over-year increase of 5.3%.

GSA Capital Partners LLP boosted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 263.0% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,904 shares of the medical research company's stock after purchasing an additional 3,553 shares during the quarter. GSA Capital Partners LLP's holdings in IQVIA were worth $865,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the stock. Premier Fund Managers Ltd boosted its position in shares of IQVIA by 8.7% in the first quarter. Premier Fund Managers Ltd now owns 250,099 shares of the medical research company's stock valued at $44,347,000 after acquiring an additional 20,099 shares during the period. Nemes Rush Group LLC boosted its position in shares of IQVIA by 15.0% in the first quarter. Nemes Rush Group LLC now owns 621 shares of the medical research company's stock valued at $109,000 after acquiring an additional 81 shares during the period. LPL Financial LLC boosted its position in shares of IQVIA by 5.8% in the first quarter. LPL Financial LLC now owns 102,121 shares of the medical research company's stock valued at $18,004,000 after acquiring an additional 5,615 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of IQVIA by 8.7% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 91,955 shares of the medical research company's stock valued at $16,212,000 after acquiring an additional 7,382 shares during the period. Finally, Empirical Finance LLC boosted its position in shares of IQVIA by 2.4% in the first quarter. Empirical Finance LLC now owns 6,374 shares of the medical research company's stock valued at $1,124,000 after acquiring an additional 152 shares during the period. Institutional investors own 89.62% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on IQV shares. Truist Financial increased their price objective on IQVIA from $209.00 to $235.00 and gave the company a "buy" rating in a research report on Wednesday, July 23rd. Barclays upped their target price on IQVIA from $165.00 to $185.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 23rd. UBS Group upped their target price on IQVIA from $185.00 to $225.00 and gave the company a "buy" rating in a research note on Wednesday, July 23rd. Mizuho upped their target price on IQVIA from $190.00 to $225.00 and gave the company an "outperform" rating in a research note on Friday, July 25th. Finally, Hsbc Global Res lowered IQVIA from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Seven research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $228.62.

IQVIA Trading Up 0.3%

IQV traded up $0.52 during midday trading on Monday, reaching $182.97. 1,100,457 shares of the company were exchanged, compared to its average volume of 2,403,455. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $252.88. The stock has a market capitalization of $31.10 billion, a P/E ratio of 26.48, a PEG ratio of 2.00 and a beta of 1.30. The stock's 50-day simple moving average is $162.11 and its 200 day simple moving average is $169.70.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping analysts' consensus estimates of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%. The company had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. During the same quarter last year, the firm posted $2.64 earnings per share. IQVIA's revenue was up 5.3% compared to the same quarter last year. As a group, analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Insider Activity at IQVIA

In other news, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the transaction, the insider directly owned 2,910 shares in the company, valued at approximately $557,352.30. The trade was a 15.87% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Eric Sherbet sold 5,800 shares of the business's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the sale, the insider owned 27,178 shares of the company's stock, valued at $5,165,178.90. This trade represents a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is owned by insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.